(MedPage Today) — BERLIN — In a global phase III trial, the addition of durvalumab (Imfinzi) to standard chemotherapy given before and after surgery led to a statistically significant and “clinically meaningful” survival improvement in patients…
Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118009
Author :
Publish date : 2025-10-17 20:23:00
Copyright for syndicated content belongs to the linked Source.
